Eupraxia Pharmaceuticals reports Q4 results
Mar. 23, 2023 5:14 PM ETEupraxia Pharmaceuticals Inc. (EPRX:CA), EPRXFBy: Pranav Ghumatkar, SA News Editor
- Eupraxia Pharmaceuticals press release (TSX:EPRX:CA): Q4 Concluded the quarter ended December 31, 2022, with cash and cash equivalents of C$24.7 million. Eupraxia anticipates its current cash is sufficient to fund the Company through to the fourth quarter of 2023.
- The Company incurred a net loss of C$9.1 million for the three months ended December 31, 2022, versus C$3.8 million for the three months ended December 31, 2021.